Procept Biorobotics Corp (PRCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Procept Biorobotics Corp (PRCT) has a cash flow conversion efficiency ratio of -0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.63 Million) by net assets ($380.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PRCT cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Procept Biorobotics Corp - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Procept Biorobotics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Procept Biorobotics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Procept Biorobotics Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TTW Public Company Limited
BK:TTW
|
0.045x |
|
First Mid Illinois Bancshares Inc
NASDAQ:FMBH
|
0.039x |
|
HHC Changzhou Corp.
SHE:301061
|
N/A |
|
Array Technologies Inc
NASDAQ:ARRY
|
0.068x |
|
Zhejiang Yonggui Electric Equipment Co Ltd
SHE:300351
|
0.002x |
|
Chicony Power Technology Co Ltd
TW:6412
|
0.072x |
|
Zhejiang Chenfeng Science and Technology Co Ltd Class A
SHG:603685
|
0.026x |
|
WHA Premium Growth Freehold And Leasehold Real Estate Investment Trust
BK:WHART
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Procept Biorobotics Corp (2019–2024)
The table below shows the annual cash flow conversion efficiency of Procept Biorobotics Corp from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Procept Biorobotics Corp (PRCT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $402.22 Million | $-99.21 Million | -0.247x | +35.88% |
| 2023-12-31 | $280.75 Million | $-108.00 Million | -0.385x | +5.69% |
| 2022-12-31 | $197.07 Million | $-80.38 Million | -0.408x | -90.01% |
| 2021-12-31 | $267.09 Million | $-57.33 Million | -0.215x | +72.93% |
| 2020-12-31 | $60.96 Million | $-48.34 Million | -0.793x | +47.10% |
| 2019-12-31 | $29.23 Million | $-43.82 Million | -1.499x | -- |
About Procept Biorobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Rob… Read more